Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/40—Peroxides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/44—Oxidoreductases (1)
  • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
  • C12Y111/01—Peroxidases (1.11.1)
  • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
  • C12Y111/01—Peroxidases (1.11.1)
  • C12Y111/0101—Chloride peroxidase (1.11.1.10)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
  • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
  • C12Y111/02002—Myeloperoxidase (1.11.2.2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present disclosure generally relates to compositions and methods for treating solid cancer. Specifically, the disclosure provides compositions comprising haloperoxidases, and methods comprising administering such compositions, for treating solid cancer.
• Cancer is a disease that is characterized by uncontrolled cell growth, almost anywhere in the body. Tumor formation is where uncontrolled cell growth occurs in solid tissue such as an organ, muscle, or bone. To this point, a large portion of the most common cancers are solid, tumor-forming cancers such as breast cancer, lung and bronchus cancer, prostate cancer, coion and rectum cancer, melanoma of the skin, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, pancreatic cancer, thyroid cancer, and liver cancer.
• Solid cancers include various cancers other than hematological cancers (lymphoma, leukemia, and multiple myeloma etc).
• Some solid cancers such as bladder, brain or spinal cord cancer, are difficult to biopsy and/or treat (surgically or non-surgically) through inaccessibility to the site of cancer growth. Accordingly, such cancers may result in high incidences of patient mortality.
• a method of treating a solid cancer comprising administering an effective amount of a pharmaceutical composition comprising a haloperoxidase.
• the disclosure provides a method of treating a solid cancer in a patient, said method consisting of administering to said patient an effective amount of a haloperoxidase, and optionally one or more of: a halide, a peroxide or peroxide producing oxidase, a substrate for said oxidase, and a pharmaceutically acceptable carrier.
• the disclosure provides a combination for treating a solid cancer in a patient, said combination comprising a haloperoxidase, and at least one of a halide, and peroxide or a peroxide producing oxidase.
• the disclosure provides a combination for treating a solid tumor in a patient, said combination consisting of a haloperoxidase, a halide, and peroxide or a peroxide producing oxidase, and optionally a substrate for said oxidase, and a pharmaceutically acceptable carrier.
• a composition for treating a solid cancer in a patient said composition comprising a haloperoxidase, and optionally one or more of: a halide, peroxide or a peroxide producing oxidase, a substrate for said oxidase, and a pharmaceutically acceptable carrier.
• the disclosure provides a composition for treating a solid cancer in a patient, said composition consisting of a haloperoxidase, and optionally one or more of a halide, peroxide or a peroxide producing oxidase, a substrate for said oxidase, and a pharmaceutically acceptable carrier.
• the haloperoxidase is selected from a group consisting of: myeloperoxidase (MPO), eosinophil peroxidase (EPO), lactoperoxidase (LPO), chloroperoxidase (CPO), functional derivatives thereof, and combinations thereof. Most preferably, the haloperoxidase is EPO.
• the haloperoxidase catalyzes halide oxidation and disproportionation of peroxide yielding singlet molecular oxygen resulting in one or more of: inhibition of cancer cell growth, inhibition of cancel cell metastases, and/or cancer cell death.
• the solid cancer is selected from the group consisting of: breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, pancreatic cancer, thyroid cancer, liver cancer, brain cancer and spinal cord cancer.
• polypeptide are used interchangeability herein.
• the 3-letter code for amino acids as defined in conformity with the IUPAC-IUB Joint Commission on Biochemical Nomenclature is used throughout this disclosure. It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code.
• enzymes such as haloperoxldase or glucose oxidase.
• an enzyme is a protein/polypeptide which acts as a catalyst to bring about a specific biochemical reaction. Included within the scope of enzymes of the present disclosure include those isolated from a natural source having the unmodified amino acid sequence identical to that found in nature, as well as “functional derivatives” thereof.
• haloperoxidase refers to an enzyme which catalyzes the hydrogen peroxide dependent oxidation of halide generating hypohalous acid; this hypohalous acid can react with an additional hydrogen peroxide to generate singlet molecular oxygen.
• a haloperoxidase according to the present disclosure may be also referred to as a halide: hydrogen peroxide oxidoreductase (e.g., EC No. 1.11.1.7 and EC No. 1.11.1.10 under the International Union of Biochemistry) for which halide, e.g., chloride or bromide, is the electron donor or reductant and peroxide is the electron receiver or oxidant.
• Suitable haloperoxidases include myeloperoxidase (MPO), eosinophil peroxidase (EPO), lactoperoxidase (LPO), chloroperoxidase (CPO), functional derivatives thereof and combinations thereof.
• the haloperoxidase may be derived from any source, including human and non-human animals.
• a “derivative” of an enzyme of the disclosure generally retains the characteristic enzymatic activity observed in the wild-type, native or parent form to the extent that the derivative is effective for similar purposes as the wild-type, native or parent form.
• a “functional derivative” when used in the contact of enzymes of the disclosure encompasses naturally occurring, synthetically or recombinantly produced nucleic acids or fragments and encode enzymes having the functional characteristics of the native, unmodified parent enzyme present disclosure.
• a “functional derivative” may include a "substituted variant” which is a variant in which at least one amino acid residue in a native sequence has been removed and inserted into the same position by a different amino acid. The substitution may be single, wherein only one amino acid in the molecule is substituted; or there may be multiple, wherein the same molecule has two or more amino acids substituted. Multiple substitutions can be located at successive sites.
• an amino acid can be substituted with multiple residues, including substitutions and insertions.
• An "insertion variant” is a variant in which one or more amino acids are inserted into an amino acid immediately adjacent to a particular position in a native sequence. Immediately adjacent to the amino acid means attached via an alpha-carboxy or alpha-amino functional group of the amino acid.
• a “deleted variant” is a variant in which one or more amino acids in the native amino acid sequence are removed. Typically, a deleted variant has one or two amino acids deleted in a particular region of its molecule.
• isolated refers to a material that is removed from its original environment (e.g. the natural environment, if it is naturally occurring).
• the material is said to be “purified” when it is present in a particular composition in a higher concentration than exists in a naturally occurring or wild type organism or in combination with components not normally present upon expression from a naturally occurring or wild type organism.
• a naturally-occurring protein/polypeptide present in a living organism is not isolated, but the same protein/polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated.
• proteins/polypeptides could, for example, be part of a composition, and still be isolated in that such a composition is not part of the natural environment of the proteins/polypeptides.
• pharmaceutically acceptable refers to substances that do not cause substantial adverse allergic or immunological reactions when administered to a patient.
• a “pharmaceutically acceptable carrier” includes, but is not limited to, solvents, coatings, dispersion agents, wetting agents, isotonic and absorption delaying agents and disintegrants.
• treat means accomplishing one or more of the following: (a) reducing the severity and/or duration; (b) limiting or preventing development of characteristic symptoms; (c) inhibiting worsening of symptoms; (d) limiting or preventing recurrence; and (e) limiting or preventing recurrence of symptoms.
• the terms include both prophylactic or preventive treatment (that prevent and/or slow the development of a targeted pathologic disease, condition or disorder) and curative, therapeutic or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a disease, condition or disorder; and treatment of a patient at risk of contracting a disease or suspected to have contracted a disease, as well as a patient who is ill or has been diagnosed as suffering from a disease, condition or disorder.
• the terms do not necessarily imply that a patient is treated until total recovery.
• the terms may also refer to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition.
• the terms may also include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measures.
• a treatment can be performed by a patient, a caregiver, a doctor, a nurse, or another healthcare professional.
• prevention means preventing that a disorder occurs in patient.
• prevention includes reduction of risk, incidence and/or severity of a disease, condition or disorder.
• the expressions “is for administration” and “is to be administered” have the same meaning as “is prepared to be administered”, in other words, the statement that an active compound “is for administration” has to be understood in that said active compound has been formulated and made up into doses so that said active compound is in a state capable of exerting its therapeutic activity.
• the terms "effective amount” or “therapeutic amount” are intended to mean that amount of a substance that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
• the term “prophylactically effective amount” is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician.
• Haloperoxidase-Containmg Compositions are Haloperoxidase-Containmg Compositions.
• Haloperoxidases are widespread in nature being produced by mammals, plants, algae, lichen, bacteria, and fungi.
• PCT/US1992/001237 discloses that haloperoxidases can be used as an antimicrobial agents (effective particularly against bacteria and fungi) as they selectively bind to target microbes and in the presence of peroxide and halide inhibiting target microbe growth.
• haloperoxidases can be used as an antimicrobial agents (effective particularly against bacteria and fungi) as they selectively bind to target microbes and in the presence of peroxide and halide inhibiting target microbe growth.
• Using limited concentrations of haloperoxidase with selective binding can inhibit target microbes without eliminating desirable microbes or causing significant damage to host cells.
• the selective nature of haloperoxidase binding makes them useful in therapeutic or prophylactic antimicrobial treatment of human or non-human patients.
• the present disclosure is predicated on the surprising and unexpected finding that haloperoxidase-containing compositions exhibit anticancer properties, in one aspect, the disclosure provides methods for treating solid cancer by contacting the cancer with a composition comprising a haloperoxidase. In another aspect, the disclosure provides compositions for treating solid cancer, said compositions comprising a haloperoxidase. In yet another aspect, the disclosure provides a combination for treating a solid cancer, said combination comprising a haloperoxidase, and at least one of a halide, and peroxide or a peroxide producing oxidase.
• the haloperoxidase catalyzes halide oxidation and disproportionation of peroxide to singlet molecular oxygen treating said cancer by inhibiting cancer cell growth, metastases and/or by cancer cell killing.
• suitable haloperoxidases according to the present disclosure include eosinophil peroxidase (EPO), myeloperoxidase (MPO), lactoperoxidase (LPO), chloroperoxidase (CPO), functional derivatives thereof and combinations thereof.
• the method of treatment of the present disclosure further comprises administering an effective amount of peroxide or a peroxide-producing oxidase.
• a substrate for the oxidase may be optionally administered.
• the peroxide- producing oxidase is glucose oxidase and the substrate is glucose.
• the method further comprises administering the haloperoxidase with a halide, preferably a chloride or bromide.
• the haloperoxidase is administered in a first composition together with at least one further composition comprising one or more of: a halide, peroxide or a peroxide-producing oxidase plus a substrate for the peroxide- producing oxidase.
• the haloperoxidase may be formulated in a composition for administration, said composition also comprising one or more of a halide, peroxide or a peroxide-producing oxidase, and a substrate for the peroxide-producing oxidase.
• eosinophil peroxidase (EPO) and myeloperoxidase (MPO) are preferred haloperoxidases for use in the present compositions, combinations and treatment methods.
• MPO and EPO are porcine derived.
• the purified haloperoxidases, porcine MPO and EPO are those produced by Exoxemis, Inc.
• the porcine MPO is preferably 98.9% pure by ultraperformance liquid chromatography (RP-LJPLC) and 100% pure by molecular size exclusion high- performance liquid chromatography (SEC-HPLC).
• the guaiacol unit (GU) activity of the porcine MPO is preferably 404GU/mg; 1.0GU of activity consumes 1.0 pmol HaOs/minute.
• Porcine EPO is preferably 99.2% pure by reversed-phase high-performance liquid chromatography.
• the guaiacol unit (GU) activity of the porcine EPO is preferably 80GU/mg.
• MPO and EPO are both cationic proteins. Without being bound by theory, it is believed that the cationic nature of such haloperoxidases makes them particularly adherent to the anionic surface of cancer cells resulting from the Warburg effect (a form of modified cellular metabolism found in cancer cells). Thus, the anticancer effect results from the electrostatic attraction and binding of the haloperoxidase to the anionic surface of cancer cells, but not to the neutrally-charged surface of normal cells.
• Haloperoxidases may differ in their physical properties and optimal conditions for enzymic activity (e.g. see US9782459). For example, MPO is around 150 kDa and is active at acidic pH (4.0 - 6.5), whereas EPO is around 70kDa and active at acidic to neutral pH (i.e. 6.5-7.4). Notwithstanding the above surprising and unexpected finding that haloperoxidases have anticancer potential, in embodiments, compositions of the present disclosure may comprise one or more haloperoxidase where the characteristics of the haloperoxidase may be aligned with the conditions of the site of cancer treatment. In embodiments, the choice of haloperoxidase is determined by the pH at the site of treatment. In other embodiments, the choice of haloperoxidase is determined by accessibility to the site of treatment.
• compositions of the disclosure will comprise from about 1 to about 100,000 pg/ml of haloperoxidase, more preferably from about 5 to about 50,000 pg/ml, and even more preferably from about 10 to about 5,000 pg/ml haloperoxidase.
• Peroxide-producing oxidases effective in the present disclosure include, for example, oxidases, such as glucose oxidase, cholesterol oxidase and galactose oxidase.
• oxidases such as glucose oxidase, cholesterol oxidase and galactose oxidase.
• the compositions of the present disclosure may comprise from about 0.05 to about 3,000 U/ml, more preferably from about 0.1 to about 1 ,000 U/ml, and even more preferably from about 1 to about 500 U/ml of glucose oxidase, and from about 0.1 to about 100 mM, more preferably from about 0.5 to about 80 mM, and even more preferably from about 1 to about 50 mM glucose.
• the glucose oxidase as used in compositions of the present disclosure is derived from Aspergillus Nisger . More preferably, the glucose
• haloperoxidases useful in the compositions, combinations or treatment methods of the present disclosure may be administered in combination with peroxide.
• Administration of peroxide, as with a peroxide-producing oxidase may be simultaneously or sequentially to the administration of the haloperoxidase.
• peroxide may be administered to a site of treatment at a concentration including, but not limited to, about 1 pM to about 100 mM, preferably about 1 mM to about 50 mM, more preferably about 9 mM.
• Administration may depend on accessibility to the site of treatment.
• a bolus of peroxide of between about 1 ml to 1000 ml, preferably 100 ml to 800 ml, most preferably 500 ml may be administered.
• the haloperoxidase may optionally be supplied to a site of treatment with at least two amino acids, preferably at least three amino acids, selected from the group consisting of glycine, L-alanine, D-aianine, L-alanine anhydride, L- glutamine, L-glutamic acid, glycine anhydride, hippuric acid, L-histidine, L-leucine, D- leucine, L-isoleucine, D-isoleucine, L-lysine, L-ornithine, D-phenylalanine, L- phenylalanine, L-proline, L-hydroxyproline, L-serine, taurine, L-threonine, D-threonine, L- tyrosine, L-valine, D-valine, beta amino acids, such as beta alanine, L-beta- homoleucine, D-beta-homoleucine, 3-a
• compositions/combinations of the disclosure will vary depending on the amount of haloperoxidase in the compositions/combinations and conditions present in the environment of use.
• the compositions may generally comprise from about 0.1 to about 500 mM, more preferably from about 0.2 to about 100 mM, and even more preferably from about 0.3 to about 50 mM of each of the amino acids of the disclosure.
• compositions/combinations of the present disclosure may optionally comprise a halide.
• the amount of chloride used in the compositions of the present disclosure will preferably fall in the range of about 10 ⁇ mol chloride to about 200 ⁇ mol per ml of solution (i.e. , 10 to 200 mEq chloride/L) chloride.
• the physiologic concentration of chloride in plasma is about 105 mEq/L.
• compositions of the present disclosure may comprise from about 0.5 pmol bromide to about 20 pmol bromide per ml (i.e., 0.5 to 20 mEq bromide/L) of liquid composition, more preferably from about 1 ⁇ mol bromide to about 10 pmol bromide per ml (i.e., 1 to 10 mEq bromide/L) of liquid composition, and most preferably from about 100 nmol bromide to about 1 ⁇ mol bromide per ml of liquid composition.
• compositions/combinations may optionally comprise a pharmaceutically acceptable carrier.
• the compositions may be conveniently provided in a liquid carrier. Any liquid carrier may be generally used for this purpose, provided that the carrier does not significantly interfere with the selective binding capabilities of the myeloperoxidase or with enzyme activity.
• the compositions may be provided in solid form with activation on solubilization in liquid.
• the haloperoxidase lends itself to construction as a binary formulation in which the composition’s active agents are formulated in two separate parts for consolidation at the time of use.
• the first composition of the binary formulation may comprise a solution containing both the haloperoxidase and the oxidase.
• the first composition may optionally comprise two or three amino acids.
• the three amino acids are glycine, l-alanine and l-proline.
• the second composition of the binary formulation may comprise a substrate for the oxidase, e g., glucose (i.e., dextrose) in the case of glucose oxidase.
• the substrate may be provided, for example, in the form of a solid wafer.
• the haloperoxidase composition may additionally comprise alcohol in order to facilitate oxidase substrate solubilization and utilization by the oxidase.
• the methods of the present disclosure comprise administering to a site, prophylacticaily or therapeutically, a combination of compositions.
• a first composition comprising haloperoxidase and a peroxide-producing oxidase may be administered (optionally comprising at least two amino acids).
• a second composition comprising a substrate for the oxidase may be separate.
• the first composition and the second composition are mixed before administration to the site of infection.
• the first composition and the second composition are administered concurrently to the site.
• the first composition and the second composition are administered sequentially to the site.
• the first composition and the second composition may be administered in any order.
• a composition of the present disclosure suitable for use as anticancer treatment may comprise from about 1 to 50,000 ⁇ g/ml haloperoxidase, from 0.01 to 500 units of glucose oxidase, and optionally: from 0.1 to 500 pmol/mL (i.e., from 0.1 to 500 mM) of glycine, from 0.1 to 500 ⁇ mol/mL (i.e., from 0.1 to 500 mM) of D- isoleucine, from 0 to 100 ⁇ mol/mL (i.e., from 0 to 100 mM) of L-alanine, and from 50 to 500 mEq/L of chloride.
• the above composition may be combined with from 1 to 500 pmol/mL (i.e., from 1 to 500 mM) of glucose or dextrose.
• the cancers targeted by the present invention are solid cancers and include various cancers other than hematological cancers (malignant lymphoma, leukemia, multiple myeloma etc).
• Typical examples of a solid cancer include lung cancer, breast cancer, stomach cancer, liver cancer, colon cancer, tongue cancer, thyroid cancer, kidney cancer, prostate cancer, uterine cancer, cervical cancer, and ovary.
• Preferred specific examples of the solid cancer include, for example, bladder cancer, colon cancer, lung cancer, pancreatic cancer, kidney cancer, or breast cancer.
• a solid cancer may also include melanoma or glioma, but is not limited thereto.
• anticancer compositions of the present disclosure can be administered in any effective pharmaceutically acceptable form to warm blooded animals, including human and non-human animal patients.
• compositions of the disclosure may be administered at any mucosal or epithelial surface.
• the compositions of the disclosure may be administered in topical, lavage, oral, vaginal or rectal suppository dosage forms, as a topical, buccal, nasal spray, aerosol for inhalation or in any other manner effective.
• the pharmaceutically acceptable carrier may take the form of liquids, creams, foams, lotions, ointments, suspensions, suppositories or gels, and may additionally comprise aqueous or organic solvents, buffering agents, emulsifiers, gelling agents, moisturizers, stabilizers, surfactants, wetting agents, preservatives, time release agents, and minor amounts of humectants, sequestering agents, dyes, perfumes, and other components commonly employed in pharmaceutical compositions for topical administration, in addition, the compositions of the present disclosure may be impregnated in dressings or coverings for application to a patient.
• anticancer compositions of the present disclosure may be administered extratumorally or intratumorally, or a combination thereof.
• an extratumoral treatment may comprise applying to the surgical site, and/or an area surrounding a surgical site, a composition/combination of the present disclosure.
• haloperoxidase may be administered in solution or in any other dosage form, such as a subcutaneous injection or deposit.
• Intratumoral treatment may comprise direct injection into a tumor or a blood vessel supplying a tumor a composition/combination of the present disclosure.
• a patient in need may be treated with a further anticancer therapy, such as an immunotherapy, chemotherapy and/or radiotherapy.
• the further anticancer therapy may be administered to the patient prior, concurrently or post treatment with the compositions/combinations of the present disclosure.
• haloperoxidase in compositions, combinations or methods of the present disclosure, will provide microbicidal benefits at the site of treatment, in addition to anticancer benefits.
• the choice of whether to administer, for example, activated haloperoxidase, or a combination of inactive haloperoxidase and peroxide producing oxidase, halide and substrate for the oxidase, will be within the remit of the person skilled in the art and may depend on numerous factors including the type and site of cancer treatment, and/or the degree of control of haloperoxidase activity required.
• Example 1 in vivo tumor reduction activity of porcine eosinophil peroxidase (pEPO)
• HT-1080 cells (Cat #CCL-121) purchased from American Type Culture
• ⁇ preservation Procedure Froze the cells in 95% complete growth medium supplemented by 5% DMSO.
• the first medium to be used after thawing the cells was Eagle’s MEM that was supplemented by adequate concentrations of glucose (4500 mg/l D-glucose).
• HT-1080 cell line propagation, harvest and viability assessment was performed prior to injection into animals revealing the following:
• SC subcutaneous
• T umor volume was calculated according to the formula for an ellipsoid:
• La, Wa, and Ha are the length, width and height of the tumor measured in vivo minus the skin thickness. Bi-fold skin thickness was subtracted from the length and width parameters and single fold skin thickness was subtracted from the height measurement to determine La, Wa and Ha.
• mice Male were purchased from Charles River Laboratories. Animals were allowed 5 days to acclimate before commencement of the study. Animals were weighed one day prior to injection. Starting body weights were between 20 and 25 grams. Animals were ear punched for identification and housed 5 per cage until randomization by tumor size. Once animals were assigned to groups, they were housed 1 per cage.
• compositions of pEPO enzyme solution and activator solution were prepared.
• the enzyme solution contained a final concentration of pEPO of 2.5pg/ml, (0.8- 0.05mM each L-alanine, L-proline, glycine, final concentration), ethanolamine (2.4- 0.15mM, final concentration), sodium bromide (2mM) and Tween-80 (0.1 %, v/v).
• the activator solution comprised hydrogen peroxide at 0.003%, v/v, 890pM in phosphate- buffered saline (PBS) pH 7.4.
• PBS phosphate- buffered saline
• HT-1080 cells fibrosarcoma cells were cultured and expanded under routine conditions noted above. On the day of injection into mice, cells were harvested, washed with phosphate buffered saline, and resuspended at a concentration 5 x 10 7 cells/ml. Thirteen athymic nude mice (13 males) were injected SC in the right flank with HT1080 cells (concentration 5.1 x 10 s cells/animal, volume 100 pl/animal). Following injection, animals were weighed weekly and monitored for tumor formation. T umors were measured twice a week using external calipers once tumors were visible and had reached a measurable size.
• mice were randomized into two groups of 5 mice.
• the tumors were surgically removed from both groups. Surgical wounds were sealed after excision of the tumor with surgical glue and then the cavity was filled with dosing solution ( ⁇ 1 ml/animal).
• Group 1 received vehicle + activator while Group 2 received of pEPO + activator.
• Animals were individually housed following surgery. One animal from Group 1 (vehicle + activator) was found dead on the day after surgery. This animal was replaced with an extra tumor bearing animal. The tumor was removed from the replacement animal, the surgical wound sealed and the cavity was treated with 1 ml of vehicle + activator.
• Example 2 Refined assessment of the in vivo tumor reduction activity of pEPO
• Example 1 A similar protocol as described in Example 1 was followed, but with slight variations. Specifically, a larger cohort of thirty-eight athymic nude mice (38 males) were injected SC in the right flank with HT-1080 cells (same concentration as used in Example 1 of 5.0 x 10 6 cells/animal, volume 100 pl/animal). Following injection, animals were weighed weekly and monitored for tumor formation. T umors were measured twice a week using external calipers once tumors were visible and had reached a measurable size.
• Example 1 tumors were allowed to reach 0.5-1 cm 3 , in this further example, tumors were allowed to reach 0.1 to 0.3 cm 3 . Animals were then randomized into two groups of 15 mice. The tumors were surgically removed from both groups. Surgical wounds were sealed after excision of the tumor with surgical glue and then the cavity was filled with dosing solution ( ⁇ 1 ml/animal). Group 1 received phosphate buffered saline while Group 2 received of pEPO activator. Animals were individually housed following surgery. Procedure according to Example 1 was otherwise followed.
• Treatment of a patient suffering from bladder cancer is envisaged and may encompass one or more of the following:
• Treatment with a bolus peroxide may comprise 0.3 to 0.03 % peroxide with 1 to 10 mEq/L bromide by lavage.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biochemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Genetics & Genomics (AREA)
• General Engineering & Computer Science (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Inorganic Chemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Molecular Biology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=81601629

Family Applications (1)

Country Status (10)

Cited By (1)

Citations (3)

Family Cites Families (3)

• 2021
  • 2021-10-01 CA CA3196357A patent/CA3196357A1/en active Pending
  • 2021-10-01 EP EP21892530.3A patent/EP4243835A4/en active Pending
  • 2021-10-01 WO PCT/US2021/053155 patent/WO2022103515A1/en not_active Ceased
  • 2021-10-01 JP JP2023527693A patent/JP2023548406A/ja active Pending
  • 2021-10-01 KR KR1020237019076A patent/KR20230106646A/ko active Pending
  • 2021-10-01 CN CN202180076110.4A patent/CN116710121A/zh active Pending
  • 2021-10-01 IL IL302683A patent/IL302683A/en unknown
  • 2021-10-01 MX MX2023005171A patent/MX2023005171A/es unknown
  • 2021-10-01 AU AU2021379542A patent/AU2021379542A1/en active Pending
  • 2021-10-01 US US18/035,480 patent/US20230398190A1/en active Pending

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events